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Abstract
Background: The 17-item Hamilton Depression Rating Scale (HDRS) is used as a semi–gold standard in research. In treatment guidelines,
the HDRS measurements serve to determine response and remission and guide clinical decision making for nonresponders. However, its use
in clinical practice is limited, possibly because the HDRS is time consuming. In addition, the multidimensional HDRS is criticized for not
measuring a unidimensional aspect as depression severity. The Maier and the Bech, two 6-item severity subscales extracted from the HDRS,
are relatively unknown. This paper investigates whether the measurements obtained with these subscales are comparable with the original
HDRS measurements.
Methods: Data from 2 randomized controlled trials in 482 male and female patients, diagnosed with a major depression (with or without
dysthymia) according to Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, of whom 219 participated in the
trials, were reanalyzed. A standardized stepwise psychopharmacological treatment was compared with a combination of pharmacotherapy
with Short Psychodynamic Supportive Psychotherapy in a psychiatric outpatient department. Outcome measures were internal consistency
and concurrent validity of HDRS, Maier, Bech, Clinical Global Impression scales, and Symptom Checklist depression subscale. Effect sizes
of HDRS, Maier, and Bech were used to compare measured treatment effects for the randomized subjects participating in the trials. Item
Response Theory was used to obtain conversion tables for the HDRS, Maier, Bech, and Symptom Checklist depression subscale.
Results: We found moderate internal consistency (Cronbach a c 0.6-0.7) and high correlations of the Maier and Bech subscales with overall
HDRS scores. Overall, there were no clinically relevant differences in effect sizes between Maier, Bech, and HDRS, although some differences
were statistically significant. Receiver operating characteristic curves showed no difference between Maier and Bech to define remission but
showed the Clinical Global Impression ratings to be unreliable. A cutoff V4 corresponded with an HDRS V7 criterion in both subscales.
Conclusion: In clinical practice, both Maier and Bech scales can be used as equivalents of the HDRS, but will be more efficient.
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Major depressive disorder is a severe disabling illness,
expected to be the world’s second health problem in 2020 [1].0010-440X/$ – see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: h.g.ruhe@amc.uva.nl (H.G. Ruhe´).Depression is associated with high costs, regarding direct
treatment and indirect costs of loss of productivity and quality
of life [2]. Several clinical guidelines were developed to
guide the treatment of this disorder; both psychotherapy and
pharmacotherapy (or in combination) appear effective [3-10].
The use of self-report or clinician-rated symptom scales is
recommended to assess severity and response to treatment
[8,11,12]. Some experts claim clinician-rated symptom
scales to have a larger validity and reliability than self-
reporting scales, especially in patients with cognitive
impairment, and more severe or psychotic depressionsiatry 46 (2005) 417–427
H.G. Ruhe´ et al. / Comprehensive Psychiatry 46 (2005) 417–427418[11,13,14]. Specific symptom scales are more reliable than
global rating scales [11,13,15] Especially, rating scales can
be used to objectively determine specific cutoff points for
response and remission [12,16,17].
In most clinical trials, the Hamilton Depression Rating
Scale (HDRS) [18,19]—a clinician-rated symptom scale—
is used as a standard to determine severity and response.
[5,8,11,15,20-23]. Many versions of the HDRS exist, with
the number of items usually varying between 17 and 24
[11,18,19,22]; however, up to 36 items have been described
[23]. Longer versions were especially developed to cover
reverse neurovegetative (atypical) symptoms [23]. The
Clinical Global Impression (CGI) [24]—a clinician-rated
global scale—is also frequently used [5,8,15,25]. In
clinical practice, although recommended, rating scales are
not used routinely. Explanations for this discrepancy could
be ignorance of existing scales, a strong belief in one’s
clinical judgement, an unsystematic approach of depres-
sion, and also the amount of time needed for rating scales
(eg, 15-20 minutes for the HDRS [11]) and the necessity of
training [20,26].
The HDRS is criticized as being sensitive to somatic
symptoms (eg, somatic illness or side effects of drugs)
[11,15,27,28], for not rating all 9 Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition domains, its
unequal weightings of different symptoms, and for the
multidimensionality of the HDRS total score [13,21,29-31].
Multidimensionality is important to cover the maximum
range of clinical features of major depressive disorder but
does not necessarily measure depression severity. Multidi-
mensional scales can be misleading when measurement of
severity and treatment response is concerned [13,21,28],
especially when the measured depressive symptoms do not
change proportionally with depression severity. Finally,
some reports emphasize that the HDRS systematically favors
(sedative) tricyclic antidepressants (TCAs) above selective
serotonin reuptake inhibitors (SSRIs) [27,32-35]. Sleep and
somatic items may appear to be bimprovedQ by side effects of
TCAs but worsened by side effects (eg, insomnia, gastroin-
testinal complaints, and agitation) of SSRIs.
To overcome the problems of the multidimensional
HDRS mentioned above, a more unidimensional subscale
from the HDRS covering core symptoms of severity is
desired. Also, from a clinical point of view, fewer items will
be less time consuming for application by busy clinicians.
However, for the purpose of reference, subscale scores must
remain anchored to the original HDRS. To identify shorter
unidimensional subscales, Maier and Philipp [28] used
Rasch and Mokken analyses, and Gibbons et al [29] used
factor analysis. Bech et al [36] developed another 6-item
subscale. This scale initially emerged from an analysis with
experienced psychiatrists as a validity criterion [36] and was
validated psychometrically thereafter using Rasch analyses
[37,38]. This Bech subscale was combined with 4 items of
the Cronholm-Ottosson Depression Scale to form the Bech-
Rafaelsen Melancholia Scale [39]. Santor and Coyne [21]examined the score performances of individual HDRS items
as a function of depression severity with a nonparametric
Item Response Theory (IRT) approach, retaining 14 items.
These 14 items included all 6 items of the Maier subscale and
all 8 items of the Gibbons subscale. However, 1 item from
the Bech subscale (13, somatic symptoms) was not included.
In a meta-analysis of individual patient data, Faries et al
[40] evaluated the responsiveness of total HDRS and
subscale scores in TCA and SSRI pharmacotherapy trials,
finding a maximal sensitivity for the Maier subscale. In a
similar reanalysis, Entsuah et al [41] found larger effect
sizes (E-S) for the Bech, Maier, and Gibbons subscales
compared with the HDRS in trials comparing SSRIs or
venlafaxine. O’Sullivan et al [20] found comparable
sensitivity to detect changes for the 6-item Bech subscale
compared with the 17-item HDRS. Hooper and Bakish [26]
found equal sensitivity to change during treatment for the
6-item Bech subscale compared with the HDRS 17-item
version. Moller [32] and Bech et al [42-44] used the Bech
subscale to reexamine treatment efficacy of SSRIs and
mirtazapine (vs TCAs or placebo). The latter publications
did not provide data for the Maier subscale.
In this paper, we describe a secondary analysis of our
trial data to answer the following questions:
(1) Are the Maier, Bech, and HDRS comparable in the
measurement of depression severity and the sensi-
tivity to measure changes in severity?
(2) Is this comparability stable across the full range of
response to treatment (eg, nonresponse, partial
response, and full response), across different treat-
ments and different baseline severity of depression?
(3) What are clinical cutoff points for the subscales to
determine remission compared with conventional
definitions [12,16,17].
We hypothesized that the differences between Maier,
Bech, and HDRS scales would be small and that there
would be no apparent effect modification across neither
treatments nor baseline severity. In contrast, we hypothe-
sized that for nonresponse and partial responders, the E-S
would be smaller than for responders. This would addition-
ally prove the hypothesis of sensitivity to change.2. Method
2.1. Patient selection
In the present analyses, we use data from 2 published,
randomized controlled trials conducted between 1993 and
1998 [45,46]. The first trial aimed at efficacy and
effectiveness of pharmacotherapy versus the combination
of pharmacotherapy with Short Psychodynamic Supportive
Psychotherapy (SPSP) [47-50] (16 sessions) [45]. The
second trial investigated efficacy and effectiveness of a
combination of pharmacotherapy with 8 versus 16 sessions
of SPSP [46]. Pharmacotherapy in both trials consisted of
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trials started with fluoxetine (20 mg/d), when this was
unsuccessful (Clinical Global Impression Improvement
[CGI-I] N2, only bminimally improvedQ or worse) after 6
weeks, amitriptyline (z150 mg/d, dependent of plasma
levels) was initiated in trial 1 and nortriptyline (z150 mg/d,
dependent of plasma levels) in trial 2. If again unsuccessful
after 6 weeks, moclobemide (300-600 mg/d) was started in
trial 1 and mirtazapine (30-45 mg/d) in trial 2.
Inclusion criteria for participation in the trials were age
between 18 and 60 years, Diagnostic and Statistical
Manual of Mental Disorders, Revised Third Edition-
defined major depression (with or without dysthymia)
assessed in a structured clinical interview, a 17-item HDRS
baseline score of at least 14 points, and written informed
consent. Patients were excluded in case of psycho-organic
or psychotic or dissociative disorders, drug abuse, or when
the patient was considered to be too unreliable to
participate in a clinical trial. Other Axis 1 comorbidity
was not excluded. Further exclusion criteria were if there
was a serious communicative or practical problem (eg,
language barrier or the patient will soon leave the country),
if there was a contraindication for 1 of the antidepressants
used, if the patient was adequately treated with antide-
pressants during the present depressive episode, if the
patient used other psychotropic medication, or if the
patient was or planned to become pregnant. Additional
exclusion criteria were of the usual kind in drug research:
btoo illQ (eg, antidepressants must be started immediately)
and/or btoo suicidalQ (eg, hospitalization is unavoidable) to
participate in a clinical trial. The study was approved by
the medical ethics committee. After complete description
of the study to the subjects, written informed consent
was obtained.
Of 3226 newly registered outpatients, 988 patients had
a depressive disorder. By initial screening, 503 of these
988 patients were excluded by the above exclusion
criteria leaving 485 subjects (including patients that later
refused to participate or had an HDRS below 14; further
referred to as the diagnostic sample). To enter the trials,
a second exclusion check was performed by a psychia-
trist (excluding 73 patients), and 142 subjects with an
HDRS-17 b14 were excluded, leaving 270 patients for
randomization. After randomization, 51 patients refused
participation, leaving 219 patients who started the
proposed therapy (further referred to as the per protocol
sample) [45,46].
In this manuscript, we used the diagnostic sample for
most cross-sectional analyses, and the randomized patients
in the per protocol sample for analyses of sensitivity of
response data. For noncompleters, the last observation was
carried forward (LOCF).
2.2. Outcome measures
Primary outcome measures were the 17-item HDRS
[18,19], the Maier subscale of the HDRS (containing items1, 2, and 7-10) [28], the Bech subscale of the HDRS (items 1,
2, 7, 8, 10, and 13) [37], the Clinical Global Impression
Severity (CGI-S) and Improvement (CGI-I) scale [24], and
the Symptom Checklist depression subscale (SCL-90dep)
[51,52]. Thus, 3 levels of information were obtained: data
from (1) an independent, trained, supervised, and blinded
research assistant (HDRS-17, Maier, and Bech), (2) the
treating clinician (CGI-S/I), and (3) the patient (SCL-90dep).
The HDRS was administered using a semistructured
interview [53]. Before participating in the study, the
reliability of the HDRS assessments was established. During
the study, to avoid slippage, audiotaped assessments were
discussed monthly.
In the analyses of treatment efficacy, response was
defined as a z50% HDRS score reduction, partial response
as z20% to 50% reduction in HDRS score, and remission
as an HDRS score of V7 points [16,54].
2.3. Statistics
Cronbach a coefficients and mean inter-item correlations
were used to express internal consistency. To check whether
the increased number of items in the HDRS accounted for a
higher Cronbach a coefficient than in the subscales (with
only 6 items), we applied the Spearman-Brown formula
[55]. Next, we calculated concurrent validity as Pearson
correlation coefficients between total HDRS, Maier, and
Bech subscale scores and SCL-90dep scores. Linear regres-
sion models calculated variance of HDRS scores explained
by the subscales [56]. These analyses were performed in our
diagnostic sample. Concurrent validity between CGI-S/I and
HDRS subscale ratings was determined also, however, to
avoid low correlations because of limited dispersion; this
was done for the last observation in the per protocol sample.
The CGI improvement scale was compared with changes
expressed as percentages of the baseline score.
To compare differences in sensitivity to measure treatment
effects (also referred to as responsiveness) in data from the
per protocol sample, E-S for HDRS, Maier, and Bech
subscales were calculated per subject as the within-subject
changes in scale scores divided by the pooled standard
deviation of the mean change in scale score
T0  Tend LOCFð Þ
SDpooleddifference

[20]. In this way, differences in E-S could be tested and 95%
confidence intervals (95% CIs) could be calculated. Differ-
ences in E-S between the scales were tested by paired t tests.
To determine significant effect modification, the above ana-
lyses were repeated while data were stratified. For stratifi-
cation, we used initial HDRS scores of at least 19 for severe
depression [11], criteria for response as described above,
and treatment condition. Differences in E-S between strata
were tested by analyses of variance (ANOVAs) models.
The Partial Credit IRT model [57] was used to estimate
the relationships between total scores on the HDRS and total
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scores were those obtained at exit (per protocol sample).
The computer program OPLM (One Parameter Logistic
Model; CITO-group, Arnhem, The Netherlands) [58] was
used to obtain a set of weights for each item in the HDRS
using conditional maximum likelihood methods. The same
software and the item weights were used to obtain estimates
of the latent trait associated with each score on the HDRS,
the Maier subscale, and the Bech subscale. The total scoresTable 1
Studied populations
Diagnostic sample
(n = 485a)
Per protocol sample (n =
Trial I [45]
AD (n = 57) AD + S
(n = 7
Sex (% female) 60.3 63.2 61.1
Age 35.3 F 9.9 34.9 F 8.2 34 F
Marital status (%)
Married 97 (20.2) 12 (21.1) 10 (13.
Divorced 60 (12.5) 7 (12.3) 8 (11.
Widowed 3 (0.6) – –
Never married 318 (66.1) 38 (66.7) 54 (75.
Other 3 (0.6) – –
Educational level (%)
Low 72 (15) 11 (19.3) 13 (18.
Intermediate 179 (37.3) 21 (36.8) 22 (31.
High 229 (47.7) 25 (43.9) 36 (50.
Occupational (%)
Job 166 (34.7) 18 (31.6) 22 (30.
On sickness 134 (28.0) 14 (24.6) 23 (31.
Social security 84 (17.5) 12 (21.1) 10 (13.
Disabled 27 (5.6) 3 (5.3) 5 (6.9
Student 41 (8.6) 5 (8.8) 10 (13.
Other 27 (5.6) 5 (8.8) 2 (2.8
Duration of episode (y)
b1 314 (67.0) 39 (70.9) 49 (70.
1-2 70 (14.9) 6 (10.9) 9 (12.
N2 85 (18.1) 10 (18.2) 12 (17.
Psychiatric treatment
during this episode (%)
95 (20.2) 13 (23.6) 9 (12.
Antidepressants last 3 mo
before study (%)
77 (16.4) 6 (10.9) 10 (14.
Of which adequate (%) 1 (0.2) – –
Depressive episodes (previous 5 y)
None 296 (63.1) 26 (47.3) 4 (58.
1-2 138 (29.4) 21 (38.2) 22 (31.
3 or more 35 (7.5) 8 (14.5) 7 (10.
Ethnicity (%)
Northwest European 414 (86.3) 51 (89.5) 63 (87.
Mediterranean 18 (3.8) 3 (5.3) 2 (2.8
Caribbean 22 (4.6) 1 (1.8) 2 (2.8
Other 26 (5.4) 2 (3.5) 5 (6.9
Baseline scores of rating scales
HDRS-17 17.1 F 6.5 21.0 F 4.8 20 F
Maier 9.2 F 3.6 11.0 F 2.9 10.9 F
Bech 9.4 F 3.7 11.5 F 2.8 11.2 F
CGI-Sd 4.7 F 0.7 4.8 F 0.6 4.7 F
SCL-90dep subscale 45.9 F 11.8 48.7 F 11.7 47.8 F
Data represent means (FSD) unless indicated. Denominators of percentages vary
a Total diagnostic sample.
b No significant differences between treatment groups (per protocol sample)
c Significant differences ( P b .05) between included and excluded patients (
d n = 241.for the pairs of scales were equated by matching the total
scores for which the latent trait scores were most similar
[59]. These methods are very similar to those used in a
previous publication about the Quick Inventory of Depres-
sive Symptomatology (QIDS) [60]. The range of SCL
scores associated with each HDRS score was obtained
directly from the original data.
Finally, receiver operating characteristic (ROC) curves
were constructed to summarize validity of cutoff points.219)b Combined I + II
Trial II [46]
PSP (16)
2)
AD + SPSP (8)
(n = 45)
AD + SPSP (16)
(n = 45)
60.0 68.9 63.0
9.4 38.1 F 10.5 36.2 F 10.5 35.5 F 9.7
9) 19 (42.2) 9 (20.5) 50 (22.9)
1) 5 (11.1) 9 (20.5) 29 (13.3)
1 (2.2) – 1 (0.5)
0) 20 (44.4) 26 (59.1) 138 (63.3)
– – –
3) 8 (17.8) 8 (18.2) 40 (18.4)
0) 20 (44.4) 16 (36.4) 79 (36.4)
7) 17 (37.8) 20 (45.5) 98 (45.2)
6) 19 (42.2) 14 (31.8) 73 (33.5)
9) 13 (28.9) 16 (36.4) 66 (30.3)
9) 8 (17.8) 3 (6.8) 33 (15.1)
) 1 (2.2) 3 (6.8) 12 (5.5)
9) 2 (4.4) 3 (6.8) 20 (9.2)
) 2 (4.4) 5 (11.4) 14 (6.4)
0) 27 (61.4) 25 (56.8) 140 (65.7)
9) 7 (15.9) 14 (31.8) 36 (16.9)
1) 10 (22.7) 5 (11.4) 37 (17.4)
9) 5 (11.4) 10 (22.7) 37 (17.4)
3) 9 (20.5) 9 (20.5) 34 (16.0)
– – –
6) 33 (75.0) 28 (65.1) 128 (60.4)
4) 10 (22.7) 13 (30.2) 66 (31.1)
0) 1 (2.3) 2 (4.7) 18 (8.5)
5) 38 (84.4) 40 (90.9) 192 (88.1)
) 1 (2.2) 1 (2.3) 7 (3.2)
) 5 (11.1) 2 (4.5) 10 (4.6)
) 1 (2.2) 1 (2.3) 9 (4.1)
4.9 19.4 F 3.8 20.3 F 4.4 20.2 F 4.6c
2.8 10.7 F 2.3 10.9 F 2.9 10.9 F 2.8c
2.7 10.7 F 2.3 11.0 F 3.0 11.1 F 2.3c
0.7 4.5 F 0.7 4.6 F 0.6 4.7 F 0.7
9.8 49.3 F 8.7 52.0 F 10.1 49.2 F 10.2c
because of missing values.
(ANOVA or v2).
independent t test).
Table 2
Internal validity and concurrent validity of HDRS-17, Maier, Bech, SCL-90 depression subscale, and CGI-S
Internal consistency Concurrent validity: Pearson r (% explained variance)
Cronbach a Mean inter-item
correlation
Overall Moderate depressiona Severe depressiona
Maier Bech Maier Bech Maier Bech
Diagnostic sample
Maierb 0.62 0.21 – – – – – –
Bechb 0.67 0.25 0.95 – 0.91 – 0.90 –
(91%) (83%) (81%)
HDRS-17b 0.73 0.13 0.86 0.86 0.57 0.76 0.65 0.60
(75%) (73%) (57%) (58%) (42%) (36%)
SCL-90 Depression subscaleb 0.88 0.33 0.64 0.64 0.45 0.45 0.40 0.42
(41%) (40%) (21%) (20%) (16%) (18%)
Per protocol sample
CGI-S end pointc NA 0.54 0.58 0.55 0.55 0.59 0.65
(29%) (34%) (31%) (30%) (34%) (42%)
CGI-I end pointd NA 0.42 0.43 0.38 0.37 0.48 0.49
(18%) (18%) (14%) (13%) (23%) (24%)
a Severe depression defined as initial HDRS-17 z19 (n = 221).
b Maier, Bech, and HDRS: n = 482; SCL-90dep: n = 473.
c CGI-S: n = 229.
d Compared with change expressed as percentage of baseline rating.
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attention for interrelation (because we studied these tests
within the same subjects) as described by Hanley andTable 3
Pretreatment and posttreatment Maier, Bech, and HDRS scores with correspondin
Mean F SD baseline Mean F SD end point (LOCF)
All subjects (n = 219)
Maier 10.9 F 2.75 6.2 F 4.46
Bech 11.1 F 2.69 6.2 F 4.50
HDRS-17 20.2 F 4.56 12.0 F 7.62
Moderate depression (initial HDRS-17 b19; n = 93)c
Maier 8.9 F 2.13 5.3 F 3.86
Bech 9.2 F 2.12 5.1 F 3.89
HDRS-17 16.2 F 1.42 9.8 F 6.15
Severe depression (initial HDRS-17 z19; n = 126)c
Maier 12.3 F 2.25 6.9 F 4.75
Bech 12.5 F 2.16 7.0 F 4.75
HDRS-17 23.1 F 3.79 13.7 F 8.18
Final nonresponders (n = 65)d
Maier 10.6 F 2.82 10.6 F 2.86
Bech 11.1 F 2.76 10.7 F 2.89
HDRS-17 19.5 F 4.25 19.9 F 4.55
Final partial responders (n = 64)d
Maier 11.5 F 2.86 7.4 F 3.07
Bech 11.4 F 2.59 7.4 F 3.19
HDRS-17 21.4 F 5.06 14.2 F 4.41
Final responders (n = 90)d
Maier 10.6 F 2.59 2.1 F 2.00
Bech 10.9 F 2.71 2.1 F 1.89
HDRS-17 19.9 F 4.28 4.8 F 3.46
Stratification by depression severity and final treatment response. Note that the
difference between these E-S (see text).
a Significantly different from E-S HDRS (paired t test; P b .05).
b Significantly different from E-S Bech (paired t test; P b .05).
c Significant differences of E-S Maier, E-S Bech, and E-S HDRS between m
d Response criteria: decrease in HDRS scores: b20% = nonresponse, 20%-
E-S Maier, E-S Bech, and E-S HDRS between categories of response (ANOVA;
e Significant differences between E-S Maier–E-S Bech, E-S HDRS–E-S Mai
f Significant difference between E-S HDRS–E-S Maier (paired t test; P b .0McNeil [61]. For all data analyses except the IRT analysis,
SPSS for Windows version 10.1 was used [62]. For all tests,
2-tailed significance levels were applied.g E-S in per protocol sample
Mean decrease (95% CI) SD of decrease E-S (95% CI)
4.7 (4.1-5.3) 4.54 1.03 (0.89-1.16)a,b
4.9 (4.3-5.5) 4.54 1.08 (0.95-1.22)
8.2 (7.2-9.2) 7.45 1.10 (0.96-1.23)
3.7 (2.8-4.5) 4.19 0.81 (0.62-1.00)b
4.1 (3.2-5.0) 4.28 0.91 (0.71-1.10)
6.4 (5.1-7.8) 6.47 0.86 (0.68-1.04)
5.4 (4.6 -6.2) 4.66 1.19 (1.01-1.37)a
5.5 (4.7-6.3) 4.65 1.21 (1.03-1.39)
9.5 (8.1-10.8) 7.88 1.27 (1.08-1.46)
0.0 (0.7-0.6) 2.65 0.01 (0.15 -0.14)e
0.4 (0.2-1.1) 2.66 0.09 (0.05 -0.24)e
0.4 (1.2-0.3) 3.08 0.06 (0.16 -0.05)e
4.1 (3.4-2.7) 2.58 0.90 (0.76 -1.04)
4.1 (3.4-4.7) 2.71 0.90 (0.75-1.04)
7.2 (6.7-7.7) 1.88 0.96 (0.90-1.03)
8.5 (7.8-9.1) 3.12 1.87 (1.72-2.01)f
8.8 (8.1-9.4) 3.14 1.93 (1.79-2.08)
15.1 (14.1-16.1) 4.89 2.02 (1.89-2.16)f
overlap of two 95% CI of E-S does not rule out a statistical significant
oderate and severe depression (ANOVA; P b .05).
50% partial response, and z50% = response. Significance differences of
P b .001).
er, and E-S HDRS–E-S Bech (paired t test; P b .05).
5).
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3.1. Patient characteristics
Table 1 shows demographics for the diagnostic and per
protocol samples. There were no significant differences
observed between the diagnostic and per protocol sample
(tested as excluded vs included), except from a lower mean
HDRS score (and Maier, Bech, and SCL-90 depression
scores) in the diagnostic sample. This difference was caused
by the application of the entrance criterion (HDRS z14) for
randomization. No significant differences existed between
the different treatment groups. The studied population
existed of mainly unmarried, mid-30s, moderately to highly
educated, female, white adults, with moderate to severe
depressive episodes of less than 1-year duration. More than
75% of the subjects were not treated for the current
depressive episode before; 16% received an inadequate trial
of an antidepressant.
3.2. Internal and concurrent validity
Data for internal and concurrent validity are presented
in Table 2. Cronbach a’s were slightly lower for the
Maier and Bech subscales. If a 17-item scale is reduced
to 6 items, the expected a is 0.49 (Spearman-Brown
formula). Thus, the observed values of 0.62 and 0.60
show increased internal validity for the subscales. The
mean inter-item correlation was markedly higher for the
Maier and Bech subscales. The correlation between Maier
and Bech subscales was high. Both Maier and Bech
subscales explained approximately 75% of the variance of
the total HDRS score. The self-rated SCL-90dep was
reasonably well correlated with the HDRS (r = 0.67) and
the Maier and Bech subscales (r = 0.64). ConcurrentTable 4
Pretreatment and posttreatment Maier, Bech, and HDRS scores with correspondi
Mean F SD baseline Mean F SD end point (LOCF)
All subjects (n = 219)
Maier 10.9 F 2.75 6.2 F 4.46
Bech 11.1 F 2.69 6.2 F 4.50
HDRS-17 20.2 F 4.56 12.0 F 7.62
AD (n = 57)c
Maier 11.0 F 2.95 7.2 F 4.97
Bech 11.5 F 2.78 7.1 F 5.01
HDRS-17 21.0 F 4.77 13.9 F 8.36
AD + 8 SPSP (n = 45)c
Maier 10.7 F 2.34 5.9 F 4.31
Bech 10.7 F 2.28 6.0 F 4.21
HDRS-17 19.4 F 3.80 11.1 F 6.80
AD + 16 SPSP (n = 117)c
Maier 10.9 F 2.82 5.8 F 4.21
Bech 11.1 F 2.78 5.8 F 4.32
HDRS-17 20.1 F 4.69 11.5 F 7.44
Stratification by treatment modality. Note that the overlap of two 95% CI of E-S
text). AD indicates antidepressants.
a Significantly different from E-S HDRS (paired t test; P b .05).
b Significantly different from E-S Bech (paired t test; P b .05).
c No significant differences of E-S Maier, E-S Bech, and E-S HDRS betwee
d Significant differences between E-S Maier–E-S Bech (paired t test; P b .0validity of the scales was overall slightly less in the more
depressed subgroup (HDRS z19; n = 194) compared
with moderately depressed subjects, except for the
correlation between HDRS and Maier subscale. The
CGI-S at study end point was moderately correlated
with the HDRS (r = 0.57), as with the Maier and Bech
subscales. The CGI-S showed higher correlation with the
Bech subscale, especially in those severely depressed. The
CGI-I at study end point was less well correlated with
the percentage change in HDRS (r = 0.42) and
the subscales.
3.3. Sensitivity to change
In Tables 3 and 4, overall and stratified E-S in the per
protocol sample are presented. In these tables, the 95% CI
of the E-S indicates whether the E-S significantly deviates
from 0 (no effect measured). Comparisons between E-S
may produce significant differences between E-S, even
when the 95% CIs between the 2 E-S overlap. Of the
9 comparisons between the Maier and Bech subscales made
in these tables, 5 were not significant. The Maier was
significantly different from the HDRS in 4 of 9 compar-
isons, whereas the Bech was significantly different from the
HDRS in only 1 of the 9 comparisons. Differences between
E-S were small.
In the total per protocol sample, the Maier subscale was
significantly less powerful to observe treatment effects: the
E-S assessed by the Maier was significantly lower than the
E-S of the Bech and HDRS. When stratified for depression
severity, the E-S of Maier, Bech subscales, and HDRS were
larger in severe compared with moderate depression. A
significant difference between these strata was observed for
all E-S (ANOVA). Within the group of severely depressedng E-S in per protocol sample
Mean decrease (95% CI) SD of decrease E-S (95% CI)
4.7 (4.1-5.3) 4.54 1.03 (0.89-1.16)a,b
4.9 (4.3-5.5) 4.54 1.08 (0.95-1.22)
8.2 (7.2-9.2) 7.45 1.10 (0.96-1.23)
3.8 (2.4-5.1) 5.12 0.83 (0.53-1.13)d
4.4 (3.1-5.7) 5.01 0.97 (0.68-1.26)d
7.1 (4.9-9.3) 8.38 0.95 (0.65-1.25)
4.8 (3.6-5.9) 3.81 1.05 (0.80-1.31)
4.6 (3.5-5.8) 3.87 1.02 (0.76-1.28)
8.3 (6.4-10.2) 6.37 1.12 (0.86-1.38)
5.1 (4.2-5.9) 4.47 1.12 (0.93-1.30)
5.3 (4.4-6.1) 4.54 1.16 (0.98-1.35)
8.6 (7.3-10.0) 7.37 1.16 (0.98-1.34)
does not rule out a statistical significant difference between these E-S (see
n treatment modalities (ANOVA).
5).
Table 5
The conversion between the HDRS total scores and the Maier subscale,
Bech subscale, and the range of SCL scores using IRT analysis (per
protocol sample)
HDRS Maier Bech Range SCL-90dep
0 0 0 –
1-2 1 1 –
3-4 2 2 –
5 3 3 –
6 3 4 –
7 (Remissiona) 4 4 –
– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
8-9 5 5 –
10-11 6 6 –
12 7 7 –
13 (Milda) 7 8 –
– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
14 8 8 31-61
15 8 9 22-59
16 9 9 26-61
17 9 10 25-59
18 (Moderatea) 10 10 30-62
– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
19 10 10 28-60
20 11 11 38-67
21 11 11 30-72
22 12 12 39-61
23 12 12 36-61
24 (Severea) 13 13 38-67
– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
25 (Very severea) 13 13 45-64
26 13 13 47-71
27 14 14 46-72
28 14 14 42-79
29 15 14 55-71
30 15 15 43-43
31 15 15 63-70
32 16 15 62-65
33 16 16 57-71
34-35 17 16 –
36 17 17 –
37-39 18 17 –
40-42 19 18 –
43-44 20 19 –
45 21 19 –
46 21 20 –
47-48 22 20 –
The only valid conversions that can be made from this table are between (1)
HDRS and Maier, (2) HDRS and Bech, and (3) HDRS and SCL-90dep.
a Cutoffs as provided by Yonkers and Samson [11].
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with the HDRS (paired t test). Within the moderately
depressed group, the Bech outperformed the Maier (paired
t test). Across different strata of final response, significant
differences in E-S were found (ANOVA). Within strata, the
Bech subscale performed less in final nonresponders,
whereas the Maier performed significantly less than the
total HDRS in final responders (paired t tests).
In Table 4, it is shown that no overall differences in
E-S were found between treatment modalities (ANOVA).
Within the group of patients treated with antidepressantsonly, the Maier subscale was significantly less sensitive to
detect treatment differences than the HDRS; however, the
Maier did not differ significantly from the Bech subscale
(paired t test).
3.4. Conversion of HDRS scores, criteria for remission, and
depression severity
Table 5 shows the conversion between HDRS scores and
Maier, Bech, and SCL-90dep scores. Maier and Bech cutoff
scores to define remission, mild, moderate, and severe
depression [11]) can be identified. Fig. 1 shows the ROC
curves for Maier, Bech CGI-S, CGI-I, and SCL-90dep cutoff
scores, with HDRS V7 as the reference criterion. The
difference in AUC for the Maier and Bech subscales was not
significant (z = 1.25; P = .21). The difference in AUC
between Maier and Bech subscales compared with
SCL-90dep and both CGIs was highly significant (z N 3.8;
P b .001). In the table below Fig. 1 sensitivity and
specificity for cutoff scores V3 and V4 for the Maier
and Bech subscales are given.4. Discussion
4.1. Major findings
This study examined the relative effectiveness of the
HDRS subscales as developed by Maier and Philipp [28]
and Bech et al [37] in monitoring severity and treatment
effects in depression. We found that the Maier and Bech
subscales gave results comparable to the original 17-item
HDRS, with high concurrent validity and increased mean
inter-item correlations and internal consistency. Maier and
Bech subscales were highly comparable to each other in the
measurement of treatment changes. Differences between
E-S were rather small and clinically irrelevant. For
interpretation, a conversion table linking HDRS scores
and Maier and Bech scores were provided. The Maier had a
slightly (nonsignificant) higher sensitivity and specificity to
predict the reference criterion for remission (HDRS V7).
Both Maier and Bech subscales differentiated nonrespond-
ers from partial and final responders.
A significant difference in sensitivity to change existed
between the Bech and Maier within the group treated with
antidepressants only. We were unable to find the reason
for this difference compared with other treatment modal-
ities, where the difference between Maier and Bech was
not found or was not significant. The question arises
whether there is a difference in sensitivity between the
Maier and Bech subscales across different treatment
modalities or that other (postrandomization) differences
between the groups or mere chance explains this
observation. Because this difference was not found in
the other groups (treated with both antidepressants and
psychotherapy), we think it cannot be ascribed to a
difference in detecting pharmacological (side) effects. If
a Bonferroni correction would be applied for the number
Fig. 1. ROC curves for Maier and Bech subscales, SCL-90 depression, and CGI-S/I at end point compared with HDRS-17 bRemissionQ in per protocol sample.
HDRS-17 score V7 (remission). Sens indicates sensitivity; Spec, specificity AUC (SE): Maier 0.972 (0.009), Bech 0.963 (0.011), SCL-90dep 0.862 (0.028),
CGI-S 0.743 (0.036), and CGI-I 0.738 (0.035).
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would not maintain its significance.4.2. The relevance of the difference between the Maier and
Bech subscales
The only difference between theMaier and Bech subscales
is the inclusion of agitation (eg, running thoughts or
restlessness, 0-4 points) in the Maier versus the inclusion of
general somatic symptoms (eg, tiredness, 0-2 points) in the
Bech. It could be argued that one scale is comparable with the
other scale without the different item; for example, the Maier
subscale would then be comparable to the Bech subscale
minus the bgeneral somaticQ item. In our (diagnostic) sample,
the item agitation contributed 1.3 (SD = 0.9) points to the
total Maier score (9.2, SD = 3.6). The general somatic item
contributed 1.5 (SD = 0.8) points to the total Bech score (9.4,
SD= 3.7). Thus, overall tiredness was more present than
agitation in this sample, and agitation was not rated near its
maximum like tiredness. Both items occurred intraindivid-
ually at the same time but were not interchangeable. This
means that the Maier and Bech subscales show different
perspectives on depressive symptoms. In this respect, it is
noteworthy to mention that the agitation item was dropped
beforehand when the Bech subscale was developed and
validated, because this item showed limited variance (ie, wasnot found to be scored) in the 2 studied samples [36,37].
Furthermore, in the Maier subscale, the items psychomotor
agitation and psychomotor retardation are included, which—
at first sight—seem to represent 2 opposed polarities.
However, these items also co-occurred within the same
individuals. This can be explained by the broad definitions of
agitation (both restlessness or running thoughts) and retar-
dation (both retardation in activities or in thinking) in our
semistructured interview.
The original HDRS is often criticized to measure somatic
symptoms [11,15,27,28]. Although the Bech subscale was
designed as an unidimensional scale, the bgeneral somaticQ
item is still among the 6 items. However, in the Rasch
analysis, this item was the least contributive and showed a
ceiling effect for moderate and severe depression [37].
Although both a Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition and International Statis-
tical Classification of Diseases, 10th revision criterion for
diagnosis, the aspecific btirednessQ symptom may also be
caused by physical illnesses. The Maier subscale does not
include this item. Thus, the Maier subscale might especially
be useful in patients having somatic complaints or illnesses.
Additional methodological support comes from the exclu-
sion of this somatic item by Santor and Coyne [21]. This
hypothesis of better performance in patients with somatic
complaints or illness needs further investigation, for
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Depression Scale [63].4.3. Previous comparative studies
Our findings are in line with findings of previous studies
[11,20,26,40-44] and extend the evidence to support the
Maier and Bech subscale as a valid alternative for the
HDRS. This is relevant not only for the planning and
conduction of clinical trials [40-42], but also for clinical
practice [20,26]. Hooper and Bakish [26] found equal
performance of the Bech subscale compared with the
Montgomery Asberg Depression Rating Scale (MADRS)
[30]. Because the MADRS was not used in our trials, we
were unable to examine the performance of the Maier
subscale compared with the MADRS. Hooper and Bakish
[26] questioned whether a possible ceiling effect in the
Bech subscale would limit its usefulness in severely
depressed patients. In our study, more than 57% of the
per protocol patients had an initial HDRS greater than 18
(indicative for severe depression) [11]. We did not find a
ceiling effect in our diagnostic sample (data not shown) and
found consequently higher E-S for the Maier and Bech
subscales in initially severely depressed patients, indicative
for an adequate sensitivity to measure (larger) changes
caused by treatment. In addition to the observed ability to
predict remission [41], we proposed cutoff scores for
remission and various ranges for classification of depres-
sion severity.
In 2 publications, Bech et al [43,44] proposed the Bech
subscale as an alternative measure to overcome the
confounding influence of drug-related side effects in the
comparison with placebo or active drugs. However, this
problem is not fully solved, as tiredness may be induced by
histaminergic effects from antidepressants (eg, tricyclics and
mirtazapine) [43]. On the other hand, agitation (included in
the Maier subscale) is known as an (mostly transient) SSRI-
induced side effect.
An extra dimension of our study is that it extends the data
for use of the Maier and Bech subscales in populations
treated with psychotherapy. Hooper et al [26] and O’Sulli-
van et al [20] already demonstrated the usefulness of the
Bech subscale in pharmacological treatment of melancholia,
dysthymia, and typical and atypical depression.
An alarming point of our study is the moderate
correlation of the Maier, Bech, and HDRS with the CGI-S
and the CGI-I. Previous reports mentioned correlations
between HDRS and CGI varying between 0.65 and
0.90 [11,28,40].Our results underscore the need of an
HDRS or subscale rating instead of the CGI. We consider
the validity of the CGI to be questionable, as most CGI
raters (subjectively) evaluate their own treatment. Appar-
ently, the clinician’s judgement does not coincide with scale
scores. In this respect, the performance of the (self-rated)
SCL-90dep is better. This was also illustrated in the ROC
curves regarding the criterion of remission. Further researchis needed to investigate whether correlations with the HDRS
of other self-rated scales (eg, the Beck Depression Inventory
[64]) are higher than the SCL-90dep. In addition to this, a
major limitation in our study and in any study investigating
depression bseverityQ is that there is no definite gold
standard. We used HDRS data as the gold standard, which
means that scales under investigation can never be judged to
be better than the HDRS; however this would be reversed if
the CGI was used as a gold standard [65].5. Conclusion
We think that both Maier and Bech subscales of the
HDRS are equivalent to the HDRS and can easily be used to
increase efficiency to measure treatment response in clinical
practice. On theoretical grounds, we have a slight preference
for the Maier subscale. The use of subscales would improve
the efficiency and objectivity of measuring response in
clinical practice, where often no scale (instead of a CGI) is
used at all. This would further bridge the gap between
clinical practice and research-based treatment recommenda-
tions for nonresponse in depression. Maier and Bech
subscales should be compared in patients having comorbid
somatic illnesses or patients treated with psychotherapy
only. The impact of the difference of the one somatic item
versus the agitation item between the Maier and Bech
subscales and the consequences for their applicability in
clinical subgroups needs further research.Acknowledgment
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